UOSD Spine Surgery, AOU Consorziale Policlinico, 70124 Bari, Italy.
PhD. Course in Public Health, Clinical Medicine and Oncology, Department DiMePre-J, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy.
Int J Mol Sci. 2023 Feb 26;24(5):4582. doi: 10.3390/ijms24054582.
Polydeoxyribonucleotide (PDRN) is a proprietary and registered drug with several beneficial effects, including tissue repairing, anti-ischemic action, and anti-inflammatory properties. The present study aims to summarize the current evidence about PRDN's clinical effectiveness in the management of tendon disorders. From January 2015 to November 2022, OVID-MEDLINE, EMBASE, Cochrane Library, SCOPUS, Web of Science, Google Scholar and PubMed were searched to identify relevant studies. The methodological quality of the studies was evaluated, and relevant data were extracted. Nine studies (two in vivo studies and seven clinical studies) were finally included in this systematic review. Overall, 169 patients (male: 103) were included in the present study. The effectiveness and safeness of PDRN has been investigated in the management of the following diseases: plantar fasciitis; epicondylitis; Achilles tendinopathy; pes anserine bursitis; chronic rotator cuff disease. No adverse effects have been recorded in the included studies and all the patients showed an improvement in clinical symptoms during the follow-up. PDRN are a valid emerging therapeutic drug in the treatment of tendinopathies. Further multicentric randomized clinical studies are needed to better define the therapeutic role of PDRN, especially in combined clinical protocols.
多聚脱氧核苷酸 (PDRN) 是一种专有的已注册药物，具有多种有益作用，包括组织修复、抗缺血作用和抗炎特性。本研究旨在总结 PDRN 在肌腱疾病管理中的临床疗效的现有证据。从 2015 年 1 月至 2022 年 11 月，对 OVID-MEDLINE、EMBASE、Cochrane 图书馆、SCOPUS、Web of Science、Google Scholar 和 PubMed 进行了检索，以确定相关研究。评估了研究的方法学质量，并提取了相关数据。本系统评价最终纳入了 9 项研究（2 项体内研究和 7 项临床研究）。总体而言，本研究纳入了 169 名患者（男性：103 名）。PDRN 在以下疾病的管理中已被研究了其有效性和安全性：足底筋膜炎；肱骨外上髁炎；跟腱病；鹅足滑囊炎；慢性肩袖疾病。纳入的研究中未记录到不良反应，所有患者在随访期间临床症状均有改善。PDRN 是治疗肌腱病的一种有效的新兴治疗药物。需要进一步进行多中心随机临床试验，以更好地确定 PDRN 的治疗作用，特别是在联合临床方案中。
